VivoSeq
Psychiatry

Opioid Use Disorder

97

Pipeline Programs↗

60

Active Trials↗

34

Companies Involved↗

Opioid Use Disorder is a moderately active landscape with 97 programs across 34 companies. The most active players are Jacques E. Chelly, Sebela Pharmaceuticals Development LLC, Protega. 36 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

53/100

Mech. Concentration

22/100

Completion Rate

69/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Jacques E. Chelly

1 program

Phase 1S

Sebela Pharmaceuticals Development LLC

1 program

Phase 1P

Protega

1 program

Phase 1T

TO Pharmaceuticals

1 program

Phase 1T

TorreyPines Therapeutics

1 program

Phase 1Eli Lilly logo

Eli Lilly

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical3

Methadone Dose

National Institute on Drug Abuse (NIDA)

Buprenorphine or Methadone Treatment

Indiana University

Dual NRT

Massachusetts General Hospital

Phase 125

Itraconazole

Sebela Pharmaceuticals Development LLC

Oxycodone

Protega

Morphine Sulfate

Merck & Co.

Remifentanil

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Drug a (blinded Drug)

University of Maryland, Baltimore

Phase 224

Tirzepatide

Eli Lilly

Lorcaserin

Eisai

Cannabidiol

Jazz Pharmaceuticals

Semaglutide

Novo Nordisk

Psilocybin

COMPASS Pathways

Phase 39

Naltrexone

Teva

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Suboxone

Merck & Co.

Opium

University of British Columbia

XR-NTX

NYU Langone Health

Approved36

Methadone

Hikma Pharmaceuticals LLC

Fentanyl

Cephalon

Prednisone

Roxane Laboratories

Olanzapine

MODAG GmbH

Propofol

Fresenius Kabi Oncology Ltd.

Analysis

Modality Breakdown

96%

Small molecule

103 of 107 classified programs — the dominant modality here.

4%ALL OTHERSPeptide44%

Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 91% of 117 pipeline programs.

Analysis

Trial Status

125

clinical trials

Completed42 · 34%
Recruiting42 · 34%
Withdrawn10 · 8%
Not yet recruiting9 · 7%
Active, not recruiting8 · 6%
Terminated7 · 6%
Other7 · 6%

Clinical Trials

Trial Activity

125 trials

Cannabidiol in Opioid Use Disorder and Chronic Pain
Recruiting·YYale University·Phase 1·NCT04587791·34 enrolled
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT04480554·225 enrolled
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
Recruiting·NNew York State Psychiatric Institute·Phase 2/3·NCT05011266·180 enrolled
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
Recruiting·NNYU Langone Health·Phase 2·NCT05722561·302 enrolled
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06655883·300 enrolled
Psilocybin for Opioid Use Disorder (OUD)
Recruiting·NNYU Langone Health·Phase 2·NCT06796062·480 enrolled
Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy
Recruiting·—·N/A·NCT05942313·100 enrolled
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
Recruiting·—·Phase 1·NCT07169409·250 enrolled
Cannabis and Opioid Use Disorder
Recruiting·UUniversity of Kentucky·Phase 1·NCT05729932·15 enrolled
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Recruiting·JJohns Hopkins University·Phase 2·NCT06067737·90 enrolled
Ketamine for Opioid Use Disorder
Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06943859·50 enrolled
OMAR Opioid Use Disorder
Recruiting·YYale University·Phase 1·NCT05683184·30 enrolled
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
Recruiting·PProniras Corporation·Phase 1·NCT06538558·40 enrolled
GLP-1R Agonist Treatment for Opioid Use Disorder
Recruiting·MMilton S. Hershey Medical Center·Phase 2·NCT06548490·200 enrolled
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Recruiting·VVA Office of Research and Development·Phase 4·NCT04375033·952 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)